Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig.

Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, Williams GR, Becker JC, Hagerty DT, Moreland LW.

N Engl J Med. 2003 Nov 13;349(20):1907-15.

2.

The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis.

Emery P.

Expert Opin Investig Drugs. 2003 Apr;12(4):673-81. Review.

PMID:
12665422
3.

Role of abatacept in the management of rheumatoid arthritis.

Nogid A, Pham DQ.

Clin Ther. 2006 Nov;28(11):1764-78. Review.

PMID:
17212998
4.

T-cell agents in the treatment of rheumatoid arthritis.

Solomon GE.

Bull NYU Hosp Jt Dis. 2010;68(3):162-5. Review.

5.

Etanercept: a review of its use in rheumatoid arthritis.

Jarvis B, Faulds D.

Drugs. 1999 Jun;57(6):945-66. Review.

PMID:
10400407
6.
7.

Safety profile of abatacept in rheumatoid arthritis: a review.

Khraishi M, Russell A, Olszynski WP.

Clin Ther. 2010 Oct;32(11):1855-70. doi: 10.1016/j.clinthera.2010.10.011. Review.

PMID:
21095481
8.

Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis.

Sibilia J, Westhovens R.

Clin Exp Rheumatol. 2007 Sep-Oct;25(5 Suppl 46):S46-56. Review.

PMID:
17977488
9.

Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.

Keating GM, Perry CM.

BioDrugs. 2002;16(2):111-48. Review.

PMID:
11985485
10.

Abatacept.

Hervey PS, Keam SJ.

BioDrugs. 2006;20(1):53-61; discussion 62. Review.

PMID:
16573350
11.

Modulation of T-cell co-stimulation in rheumatoid arthritis: clinical experience with abatacept.

Laganà B, Vinciguerra M, D'Amelio R.

Clin Drug Investig. 2009;29(3):185-202. doi: 10.2165/00044011-200929030-00005. Review.

PMID:
19243211
12.

Clinical and patient-reported outcomes in clinical trials of abatacept in the treatment of rheumatoid arthritis.

Massarotti EM.

Clin Ther. 2008 Mar;30(3):429-42. doi: 10.1016/j.clinthera.2008.03.002. Review.

PMID:
18405783
13.

Co-stimulatory blockade as therapy for rheumatoid arthritis.

Mackie SL, Vital EM, Ponchel F, Emery P.

Curr Rheumatol Rep. 2005 Oct;7(5):400-6. Review.

PMID:
16174492
14.

[A novel treatment option in rheumatoid arthritis: abatacept, a selective modulator of T-cell co-stimulation].

Dejaco C, Duftner C, Wipfler E, Schirmer M.

Wien Med Wochenschr. 2009;159(3-4):70-5. doi: 10.1007/s10354-008-0590-3. Review. German.

PMID:
19247593
15.
16.

Abatacept in biologic-naïve patients and TNF inadequate responders: clinical data in focus.

Sherrer Y.

Curr Med Res Opin. 2008 Aug;24(8):2283-94. doi: 10.1185/03007990802223129. Epub 2008 Jun 27. Review.

PMID:
18590608
17.

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.

Clark W, Jobanputra P, Barton P, Burls A.

Health Technol Assess. 2004 May;8(18):iii-iv, ix-x, 1-105. Review.

18.

[CTLA4-Ig (abatacept)].

Harigai M.

Nihon Rinsho. 2007 Jul;65(7):1231-7. Review. Japanese.

PMID:
17642237
19.

Selective costimulation modulation with abatacept: a look at quality-of-life outcomes in patients with rheumatoid arthritis.

Shergy WJ.

Semin Arthritis Rheum. 2009 Jun;38(6):434-43. doi: 10.1016/j.semarthrit.2008.03.009. Epub 2008 Jun 9. Review.

PMID:
18538830
20.

Abatacept: a novel therapy approved for the treatment of patients with rheumatoid arthritis.

Lundquist L.

Adv Ther. 2007 Mar-Apr;24(2):333-45. Review.

PMID:
17565924
Items per page

Supplemental Content

Write to the Help Desk